RNA, U4 small nuclear 23, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU4-23P profile across patient tissues and cancer cell-line models. RNU4-23P expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, RNU4-23P is differentially expressed in 7, with the highest sampling consensus in KIRP. Additionally, RNU4-23P RNA expression shows 15,022 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight DLBC, KIRP, and THYM as cancer lineages where RNU4-23P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU4-23P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU4-23P survival associations across molecular data types. RNU4-23P RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU4-23P RNA expression–survival associations across cancer types. High RNU4-23P expression shows unfavorable associations in DLBC, LGG, STAD, ACC and GBM, but favorable associations in KIRP. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for RNU4-23P RNA expression.
This table summarizes RNU4-23P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for RNU4-23P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU4-23P shows lower tumor expression in KIRP, LUSC, THCA and KICH and higher tumor expression in BLCA and CHOL. The KIRP box plot shows higher RNU4-23P RNA expression in normal versus tumor tissue (log2 FC = −0.444, t-test p = .003).
This table shows molecular features associated with RNU4-23P in patient tissues and cancer cell lines. In patient samples, RNU4-23P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
